
Index

A

AEDs. *See* Antiepileptic drugs (AEDs)

ALV. *See* Avian leucosis virus (ALV)

Animal models

brain tumors, 165, 166

EGFR-driven gliomas, 171

N-ethyl-*N*-nitrosourea (ENU), 166, 173

GEM models, 166–169

IDH1/2, 171–172

PDGF-driven gliomas (*see* Platelet-derived growth factor (PDGF))

xenografting tumor, 166

xenograft models, 172–173

Antiepileptic drugs (AEDs), 195–196, 284

Apparent diffusion correlation (ADC), 221, 225, 228–229

ATX. *See* Autotaxin (ATX)

Autotaxin (ATX), 488

Avian leucosis virus (ALV), 170

B

BBB. *See* Blood-brain barrier (BBB)

Biomathematical modeling

image-based personalized model, 450–454

transition, higher grade

anaplastic transformation, 454

kinetic classification, 456

pathways, neoangiogenesis, 455

PIHNA, 455

Blood-brain barrier (BBB), 236–238

Brain hodotopy, subcortical connectivity

axonal and minimal common brain

anatomy-functional correlations, 341

and cortical function, 340

input and output sites, 341

multiprocessing, 341

white matter circuitry, 342

naming process, intraoperative mapping

brain connectivity, 344

cognitive functions, 344

indirect ventral stream, 343

phonemic paraphasia, 343

visual perception and recognition, 342

Brain plasticity

cerebral

behavioral consequences, 338

“connectomics”, 339

“eloquent” and “non-eloquent” regions, 338

cognitive functioning, 284

DLGG time course and brain reorganization

preoperative functional neuroimaging, 340

“recovery”, 339

experimentations, animals, 350

multistage surgical approach, 349–350

neoadjuvant chemotherapy, 351

neurooncology, 337

postoperative functional neuroimaging, 350–351

reshaping, cerebrum

Broca’s area resection, 345

dominant/parietal posterior lobe resection, 349

“eloquent” areas, 345–348

insular resection, 348

maximal surgical resection, 344

precentral gyrus, 345

resection, face sensorimotor area, 348

resection, upper limb motor area, 348–349

somatosensory area resection, 349

supplementary motor area resection, 349

Wernicke’s area resection, 345

white matter pathways, 349

subcortical connectivity (*see* Brain hodotopy, subcortical connectivity)

Brainstem gliomas, 432

Brain tumor epidemiology consortium (BTEC), 23–24

BTEC. *See* Brain tumor epidemiology consortium (BTEC)

C

CAF. *See* Cancer-associated fibroblasts (CAF)

Cancer-associated fibroblasts (CAF), 139, 143, 154

Cancer stem cell (CSC), 156

CDT. *See* Cumulative dose threshold (CDT)

Central nervous system (CNS), 76

Chemotherapy, DLGG

after surgery and radiation therapy, 415–416

armamentarium, 419

benefit-to-risk ratio, 442

clinico-radiological factors, 413

and cognition, 409

cognitive disorders, 418

- Chemotherapy, DLGG (*cont.*)
 control, tumor volume, 440–441
 data and chronology, 404–407
 and epilepsy, 408
 grade II/III gliomas, 441
 molecular biology, 413–415
 neoadjuvant, 441
 neurological sensory-motor and visual functions, 418
 pathological phenotype, 413
 PCV, 404, 407, 418
 potential neurotoxicity, 404
 and quality of life (QoL), 409–410
 before radiotherapy, 416–417
 randomized trials, 415
 resectability, tumor behavior/brain plasticity/
 treatment, 441
 retreatment, 418
 speech therapy and cognitive rehabilitation, 420
 and survival, 410
 SWOG, 404
 temozolomide, 441
 TMZ, 407, 417–418
 tolerance, 410–412
 treatment, 412–413
 tumor progression, 404
 volumes, and growth rate, 407–408
- Childhood pilocytic astrocytomas (CPAs)
 peritumoral tissue, 126
 proteins, 123
- Chromosomal abnormalities
 AIIIs, 102
 OIIs, 102
- Clinical target volumes (CTV), 428, 431, 432
- CNS. *See* Central nervous system (CNS)
- Cognitive functioning, DLGG
 AED, 284
 attentional system, 281
 description, 280
 evaluation, language, 287, 288, 295
 executive functions, 282
 fatigue, 284
 intraoperative assessment
 anatomo-functional correlations, 292
 disorders, surgery, 292–295
 HH, 291
 language, 288–289
 monitoring voluntary movement, 289
 social cognition, 291–292
 surgery, 291
 USN, 290
 language, 280, 281
 memory, 281
 motor and reflexive praxis, 287
 neural networks, 287
 neurocognitive assessment, 296
 perioperative assessments, 285, 286
 postoperative and preoperative assessments, 285
 psychological support, 296
 questionnaire/complaints inventory, 285, 295
 social cognition, 282
 surgical management, 283–284
 therapeutic strategies, 282, 283
 tumor location, 295–296
- Cognitive rehabilitation. *See* Functional rehabilitation
- Continuous human cell lines, 139–142
- CPAs. *See* Childhood pilocytic astrocytomas (CPAs)
- CSC. *See* Cancer stem cell (CSC)
- Cumulative dose threshold (CDT), 411
- D**
- Database for Annotation, Visualization and Integrated
 Discovery (DAVID)
 IPA, 119
 protein clusters, 128
- DAVID. *See* Database for Annotation, Visualization and
 Integrated Discovery (DAVID)
- DES. *See* Direct electrostimulation (DES)
- Diffuse astrocytoma (AII)
 chromosomal abnormalities, 102
 clinical correlations, 106
 histologic variants, 100
 molecular investigations, 100–101
- Diffuse low-grade gliomas (DLGGs)
 adjusted odds ratios, 22–23
 age, 17–18
 animal models, 4
 biomathematical modeling (*see* Biomathematical
 modeling)
 and brain plasticity (*see* Brain plasticity)
 BTEC, 23–24
 cellular and subcellular scales, 249–250
 chemotherapy, dynamic multimodal therapeutic
 strategies, 440–442
 clinical and neurological status, 18
 clinical applications, 258, 259
 disconnection syndromes, 182
 early detection, 25–26
 FBTDB, 25
 fMRI, 186
 GC, 54
 genetic causes, 25
 glioblastomas, 24
 growth, 362
 IDH1-mutation, 53
 incidence, 15
 irradiation, 442–443
 ITC, 250
 LGG, 14
 malignant transformation and survival, 363
 McDonald's criteria, single treatment effect
 changes, VDE, 463
 equivalent diameter evolution, 462, 463
 estimation, tumor size, 463
 objective criteria, 461, 463
 slowed down group, 463

- stabilized and reversed classes, 463–464
 - uncontrolled growth, 464
- median age, diagnosis, 12, 14
- migration, 362–363
- MRS, 183, 184
- multistage surgical approach, 439–440
- neurofibromatosis type I, 180
- non-contrast and gadolinium contrast, 182, 183
- non-enhancing mass, 180–181
- oligodendroglioma, 22, 250
- oncology, objectives, 460
- PCNSTs (*see* Primary central nervous system tumors (PCNSTs))
- perfusion MRI, 183–185
- PET
 - BBB, 237
 - biopsy, 239–240
 - ¹¹C-Choline, 237
 - diagnosis, 239
 - DTI, 244
 - DWI, 244
 - [¹⁸F]3'-deoxy-3'-fluorothymidine (FLT), 237
 - ¹⁸F-fluorodeoxyglucose (FDG), 236–237
 - hybrid PET-MRI systems, 244–245
 - hypoxia, 238
 - [Methyl-¹¹C]-L-methionine (MET), 238
 - O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET), 238
 - radiolabeled amino acids, 244
- prevalence rates, 17
- prognostic factors, 17
- prognostic scores, 19
- proportion, 12
- radiotherapy, 257–258
- role, biopsy, 367–368
- sex ratio, 12
- surgery, 256–257
- surgical data, 14
- surgical resection (*see* Surgical resection, DLGG)
- survival, 15–16
- therapeutic prognostic factors, 19–20
- time, QoL vs. malignant progression, 460–462
- tonic-clonic seizure, 180
- tumor behavior and consequences, brain functions, 438, 439
- tumor involvement, cortex, 370, 373
- tumor location
 - frontal lobe, 181
 - parietal lobe, 182
 - temporal lobe, 181–182
- “wait and see” dogma, 438
- Diffusion tensor imaging (DTI)
 - clinical fMRI, 312
 - defined, 381
 - and dissection, 389
 - indices derived, sequences, 453
 - interpretation, fMRI, 314
 - limitation, 316
 - MR tractography, 306, 307, 309
 - probabilistic and Q-ball tractography, 305
 - tractography
 - ametric and nonparametric models, 304
 - brain tumors, 304
 - diameter size, axons, 304
 - FA, 303–304
 - Gaussian distribution, 303
 - HARDI methods, 304
 - MR tractography, 304
 - neuroscience, 304
 - water diffuses, 303
- Diffusion-weighted imaging (DWI), 221, 229, 244
- Direct electrostimulation (DES)
 - detection and preservation, neural connectivity
 - arcuate fascicle (AF), 388
 - brain reorganization, 386
 - glioma, 391
 - inferior longitudinal fascicle, 391
 - interhemispheric white matter pathways, 391
 - intrasurgical language mapping, 391
 - language pathways, 387
 - loco-regional language pathways, 388
 - motor pathways, 386–387
 - pathways, lesion removal, 386
 - pathways, spatial cognition, 391
 - somatosensory tracts and optic radiations, 387
 - subcortical DES, 388–389, 391
 - ventral premotor cortex and inferior frontal gyri, 387–388
 - “functional neuronavigation”, 382
 - intraoperative cortical mapping
 - advantages, 384–385
 - avoidance, seizures, 384
 - objectives, 383
 - positive and negative mapping, 384
 - stimulation, awake patients, 383
 - intraoperative monitoring, 382–383
 - intrasurgical cognitive monitoring and test selection, 385–386
 - resection, functional boundaries, 389–390, 392
- DLGGs. *See* Diffuse low-grade gliomas (DLGGs)
- DTI. *See* Diffusion tensor imaging (DTI)
- DWI. *See* Diffusion-weighted imaging (DWI)
- E**
 - ECM. *See* Extracellular matrix (ECM)
 - EGFR. *See* Epidermal growth factor receptor (EGFR)
 - Electroencephalography (EEG)
 - correlated fMRI, 333
 - MEG signal, 323
 - EOR. *See* Extent of resection (EOR)
 - EORTCs. *See* European Organization for Research and Treatment of Cancer (EORTCs)
 - Epidermal growth factor receptor (EGFR)
 - driven gliomas, 171
 - oligodendrogliomas, 173
 - Epigenomic abnormalities
 - diffuse astrocytoma, 105–106
 - OIs, 106

- Epileptic seizures
 anticonvulsive treatment
 AED, 195–196
 medically refractory seizures, 196–197
 radiotherapy and chemotherapy, 197
 surgery, 197–199
 asymmetric tonic, 194
 brain tumor, 191
 clinical trials, 201
 cognitive impairment, 190
 epileptogenesis (*see* Epileptogenesis)
 focal epileptic syndromes, 194
 focal seizures, 194
 ILAE, 191
 occipital lobe tumors, 195
 status epilepticus, 195
 temporal lobe lesions, 194
 tonic-clonic seizures, 191
 tumor evolution
 cognitive/neurological dysfunction, 199
 diagnosis, 200
 focal neurological deficits, 199
 seizure control, 200
 tumor-related factors, 190
- Epileptogenesis
 denervation hypersensitivity, 192
 high-grade gliomas, 192
 peritumoral cortex, 193–194
 seizure-related structural changes, 193
- European Organization for Research and Treatment of Cancer (EORTCs)
 advantage, postoperative radiotherapy, 19
 “nonbeliever trial”, 426, 427
- Extent of resection (EOR)
 estimation, 367–368
 function-guided surgery, 369–371
 intraoperative mapping, 478
 maximization, 479
 neuroimaging and assessment, 363–364
 OS, malignant transformation, 364
- Extracellular matrix (ECM)
 glioma cells, 488
 rigidity, 489
 and tumor cells interactions, 488
- F**
- FBTDB. *See* French Brain Tumor DataBase (FBTDB)
- FC. *See* Functional connectivity (FC)
- FLAIR. *See* Fluid-attenuated inversion recovery (FLAIR)
- Fluid-attenuated inversion recovery (FLAIR)
 hypersignals, 452, 453
 MRI, 363, 364, 368, 450, 451
 signal abnormalities, 26
 VDE, tumor measurements, 455
- fMRI. *See* Functional MRI (fMRI)
- Foix-Chavany-Marie syndrome, 348
- Fractionated stereotactic radiotherapy (FSRT)
 description, 429
 evaluations, carbon ion radiotherapy, 431
- French Brain Tumor DataBase (FBTDB)
 DLGG, 12
 PCNST, 25
- FSRT. *See* Fractionated stereotactic radiotherapy (FSRT)
- Functional connectivity (FC)
 and anatomical
 defined, 468
 MEG, 469
 neuropsychological performances, 469
 spatial reconstruction, 468
 structural plasticity, 468
 measurements, 323
- Functional MR and diffusion MR imaging
 clinical imaging protocols, 302–303
 clinical use, 302
 description, 301
 DTI and tractography (*see* Diffusion tensor imaging (DTI))
 ESM, 302
 feasible brain mapping imaging protocols, 304–305
 interpretation, clinical studies, 314–315
 mapping functional networks
 current issues, mapping speech, 309–310
 dorsal language pathway, 307
 language, 305–307
 sensorimotor, 305
 structures, 305
 ventral language pathway, 307–309
 visuospatial attention, 310–312
 methods limitations, 316
 operating room, 315–316
 slow-growing gliomas, 312–314
 therapeutic strategies, neuro-oncology, 301–302
- Functional MRI (fMRI)
 correlations, intraoperative electrophysiology, 381
 diffusion MR imaging (*see* Functional MR and diffusion MR imaging)
 and DTI, 381
 laterality index, language, 381
 patients, brain tumors, 323
 resting-state study, 326
 silent-word generation paradigm, 332
- Functional neuroimaging, DLGG
 brain remapping, 393–396
 DES (*see* Direct electrostimulation (DES))
 fMRI and DTI, 381
 gliomas, 380
 hemispheric language lateralization, 380–381
 hippocampal resection, 393
 intraoperative stimulation, 393
 lateralization index, 381
 neurocognitive assessment, 379–380
 preservation, QOL, 378
 tumor location, 393
- Functional rehabilitation
 cognitive
 functional network reshaping, brain plasticity, 469–470
 hyper-individualized approach, 472–473
 objectives, 469
 description, 465–466

- FC and anatomical connectivity, 468–469
- longitudinal follow-up, 472
- mechanisms, recovery
 - brain plasticity, 467
 - compensation and restoration, 466
 - neural networks, 467
- objectives, 469
- postoperative, 470–472
- preoperative, 472
- slow-growing tumor, functional plasticity, 467–468
- Functional vs. molecular theory, DLGG
 - brain locations, 484–485
 - cellular and ultrastructural mechanisms
 - ATX, 488
 - GBMs, 490
 - glioma cells, 488
 - interactions, 486
 - microglial cells, 487–488
 - NF1, 487
 - OPC, 489–490
 - phenotypic cell, 488
 - stroma, 487
 - supratentorial and infratentorial gliomas, 489
 - tumor cells, 486–487
 - cytochemoarchitectonics, 486
 - diffusion-proliferation process, 484
 - dynamic interactions, DLGG and brain, 490
 - factors, 491
 - SMA and insula, 485
 - SVZ, 486
- G**
- GBM. *See* Glioblastoma multiforme (GBM)
- GBMs. *See* Glioblastomas (GBMs)
- GC. *See* Gliomatosis cerebri (GC)
- Genetically engineered mouse (GEM) models
 - genomic changes, 166
 - human brain tumors, 166
 - transgenic rodents, 166–169
- Genomic abnormalities
 - IDH, 103
 - PDGFR, 104
 - TP53 gene, 102–103
 - TYRO3 gene, 104
- GFAP. *See* Glial fibrillary acidic protein (GFAP)
- G2Gs. *See* Grade II gliomas (G2Gs)
- Glial and precursor cells
 - NSCs, 77
 - OPC, 76
 - SVZ, 77
- Glial fibrillary acidic protein (GFAP), 170
- Glioblastoma multiforme (GBM)
 - LGG, 121
 - proteomics, 133
 - α -tubulin, 128
- Glioblastomas (GBMs)
 - de novo and secondary, 486
 - and stromal cells, 488
- Glioma classifications
 - anaplasia, 35–36
 - astrocytomas, 33
 - Bailey and Cushing, 32–33
 - brain tumors, 32
 - fibrillary astrocytomas, 33
 - gemistocytic astrocytoma, 35
 - low grade astrocytoma, 33, 34
 - oligo-astrocytomas, 37
 - oligodendroglioma, 34–35
 - protoplasmic astrocytomas, 33
 - WHO, 32
- Glioma stem cells (GSC), 143, 146, 147, 151, 154
- Gliomatosis cerebri (GC)
 - astrocytoma and oligodendroglioma, 55
 - chemotherapy, 54
 - clinical presentation, 47–48
 - definition, 46–47
 - disease associations, 48
 - epidemiology, 47
 - genetic anomalies, 50
 - grade, 50
 - IDH1-2 mutation, 52
 - IHC, 50
 - macroscopic examination, 48, 50
 - microscopic examination, 50
 - prognosis, 52–53
 - radiological features, 48
 - radiotherapy, 53
 - WHO, 46
- Grade II gliomas (G2Gs)
 - astrocytoma and oligoastrocytoma tumors, 82
 - cellular origin, 78
 - CNS, 76
 - glial and precursor cells, 76–77
 - IDH1, 78
 - oligodendrocytes and Schwann cells, 75–76
 - oligodendroglioma tumors (*see* Oligodendroglioma tumors)
 - OPCs, 83–84
 - tumor cell heterogeneity, 79
- Gross tumor volumes (GTV), 428, 431, 432
- GSC. *See* Glioma stem cells (GSC)
- GTV. *See* Gross tumor volumes (GTV)
- H**
- HARDI. *See* High angular resolution diffusion imaging (HARDI)
- Health-related quality of life (HRQOL)
 - methodological issues and limitations, 210–211
 - patients
 - chemotherapy, 213
 - clinical practice, 214
 - diagnosis and treatment, 211–212
 - disease recurrence, 212
 - disease-specific signs and symptoms, 212
 - radiotherapy, 211, 213
 - supportive treatment, 213
 - surgery, 212–213
 - tumors, 212
 - questionnaires, 207–210
- HGG. *See* High grade glioma (HGG)

HH. *See* Homonymous hemianopsia (HH)
 High angular resolution diffusion imaging (HARDI), 304, 307, 313, 316
 High grade glioma (HGG)
 LGGs (*see* Low-grade gliomas (LGGs))
 malignant transformation, 128
 protein changes, 123
 proteomics, 126–127
 Histological classification
 description, 32
 glioma classifications (*see* Glioma classifications)
 Sainte Anne's Hospital classification
 (*see* Sainte Anne's Hospital classification)
 Homonymous hemianopsia (HH), 291
 HRQOL. *See* Health-related quality of life (HRQOL)
 Human LGG cultures
 bone marrow mesenchymal stem cells, 139
 CSC, 156
 drug-screening assays, 156
 GBM, 156
 in vitro models
 brain tumor-initiating cells, 143
 CAF, 143
 cancer stem cells, 139, 143
 continuous human tumor cell lines, 139
 drug-screening strategies, 144
 GBM stem cells, 144
 PDGF, 144
 short-term culture, 139
 tumor cell lines characterization, 139–142
 in vivo models, 139
 immortalized tumorigenic cell lines, 144–145
 methods, 156
 parenchymal cell lines (*see* Tumor-associated parenchymal cell lines)
 pediatric tumors, 157
 personalized medicine, 156
 short-term cell lines, 145–146
 treatment-independent factors, 138
 tumor-initiating cells (*see* Tumor-initiating cells, glioma-derived)
 Hyper-individualized approach, cognitive rehabilitation, 472–473

I

IDH. *See* Isocitrate dehydrogenase (IDH)
 IDH1. *See* Isocitrate dehydrogenase 1 gene (IDH1)
 IDLGGs. *See* Incidental diffuse low-grade gliomas (IDLGGs)
 IFOF. *See* Inferior fronto-occipital fasciculus (IFOF)
 IHC. *See* Immunohistochemistry (IHC)
 ILAE. *See* International League Against Epilepsy (ILAE)
 Image-based personalized model
 ADC, 453
 assessment, tumor dynamics, 451–453
 backward extrapolation, 454
 evaluations, treatment efficacy, 454
 integration, longitudinal multimodality imaging, 453

model-guided optimization, treatment sequence, 453–454
 product and ratio, Dr, 451, 452
 proliferation and migration, glioma cells, 450, 451
 virtual imaging, 451, 452
 visibility threshold hypothesis, 450–451
 Immortalized tumorigenic cell lines, 144–145
 Immunohistochemistry (IHC)
 DLGG, 50
 GC, 50
 IMRT. *See* Intensity-modulated radiotherapy (IMRT)
 Incidental diffuse low-grade gliomas (IDLGGs)
 and characteristics, 478–479
 growth rate, 481
 maximal resection, 478
 surgical management
 functional structures, 480–481
 oncologic, 479, 480
 Inferior fronto-occipital fasciculus (IFOF), 251
 Intensity-modulated radiotherapy (IMRT), 429–430
 International League Against Epilepsy (ILAE), 191
 Isocitrate dehydrogenase 1/2 (IDH1/IDH2), 171–172
 Isocitrate dehydrogenase-1 (IDH1)
 gliomas, 134
 LGG, 131
 Isocitrate dehydrogenase (IDH), 103
 Isocitrate dehydrogenase 1 gene (IDH1), 78
 Isolated tumor cells (ITC), 250
 ITC. *See* Isolated tumor cells (ITC)

K

Klinger's method, 386

L

LGGs. *See* Low-grade gliomas (LGGs)
 LOH. *See* Loss of heterozygosity (LOH)
 Loss of heterozygosity (LOH), 62
 Low-grade diffuse glioma
 astrocytic and oligodendroglial, 68–69
 diagnosis, 68
 genetic alterations, 63–64
 glioblastomas, 62
 IDH1 and *TP53* mutations, 63
 IDH1/2 mutations, 65
 LOH, 62
 molecular classification, 67–68
 oligoastrocytoma, 62
 oligodendroglioma, 61–62
 1p/19q loss, 65–66
 TP53 mutations, 65
 WHO grade III, 61
 Low-grade gliomas (LGGs)
 ADL, 215
 bioinformatics analysis, 120
 brain tumor patients, 205–206
 cancers, 214
 CAT, 215
 cognitive functioning and HRQOL, 206

- cognitive testing, 214–215
 - and control tissue, 123
 - CPAs, 126
 - DAVID, 120
 - description, 266
 - vs. HGG (*see* High grade glioma (HGG))
 - HRQOL (*see* Health-related quality of life (HRQOL))
 - human biopsy proteomic literature, 120–123
 - IDH1 mutation, 131
 - IPA, 125
 - MEG (*see* Magnetoencephalography (MEG))
 - molecular markers, 267
 - MRI, 266
 - PRKACA, 132–133
 - prognostic factors
 - age, 267
 - clinical presentation, 268
 - molecular factors, 270–271
 - oligodendrogliomas, 269
 - PET findings, 269–270
 - physiologic neuroimaging findings, 269
 - structural neuroimaging findings, 268–269
 - prognostic scoring systems, 271
 - protein changes, 123–125
 - spontaneous clinical and neuroimaging factors, 267
 - STMN1 and AKAP9, 133
 - traditional outcome measures, 206–207
- Low-grade oligodendroglioma
- characterisation, 80
 - EGFR pathways, 83
- M**
- Magnetic resonance imaging (MRI)
- acquisition, 373
 - and cell density, 451
 - cognition, “wait-and- see” follow-up, 255
 - 3D-MRI atlases, 450
 - DTI, 450
 - FLAIR, 450, 451
 - low-grade gliomas, 242
 - low-grade phase
 - qualitative, 251, 252
 - quantitative, 252–254
 - perfusion, 183–185
 - PET, 239
 - pregnancy, 256
 - radiological tumor growth, 255
 - serial images, 450
 - signal abnormality, control, 364
 - silent phase, 251
 - T2-/FLAIR-weighted, 364, 368
 - T1-gado MRI, 454
 - transition, glioma, 254–255
 - VDE, 256
- Magnetic resonance spectroscopy (MRS)
- FLAIR image, 183, 184
 - high- and low-grade tumors, 183
- Magnetoencephalography (MEG)
- brain dysfunction exists, 321
 - brain tumors, 323–325
 - EEG, 323
 - epilepsy, 332–333
 - functional connectivity and clinical applications, 331–332
 - low-grade glioma patients, 327–331
 - measurement, 323
 - MRI technique, 322–323
 - neural network research, 333–334
 - oncological mechanisms, 323
 - small-world phenomenon, 325–327
 - structural, functional and effective connectivity, 322
- MAPK. *See* Mitogen-activated protein kinase (MAPK)
- MASCs. *See* Multipotent adult stem cells (MASCs)
- Matrix metalloproteases (MMPs), 487
- Mean tumoral diameters (MTD), 408, 417, 418
- MEG. *See* Magnetoencephalography (MEG)
- Metabolic-oncological MR imaging
- conventional magnetic resonance, 219
 - description, 219
 - diagnosis
 - in vivo* spectroscopy, 221–224
 - metabolic modifications to increased perfusion, 224–225
 - prognosis, 220–221
 - postradiation changes/glioma progression, 228–229
 - therapeutic follow-up, 225–228
 - tumor energy metabolism, 229–231
- Mitogen-activated protein kinase (MAPK), 170
- MMPs. *See* Matrix metalloproteases (MMPs)
- Molecular and cellular basis, DLGGs
- CD44s expression, 93
 - glioma cell dissemination, 92
 - hyaluronan, 93
 - in vitro* models, 92
 - infiltrated tumoral cell, 95
 - migration, 92–93
 - migratory vs. nonmigratory glioma cells, 95–96
 - OG, 93–94
 - residual tumoral cells, 92
 - white and gray matters, 96
- Molecular biology, DLGGs
- AII, 100–101
 - molecular classification, 108–109
 - WHO grade III and IV, 100
- Molecular theory. *See* Functional vs. molecular theory, DLGG
- MRI. *See* Magnetic resonance imaging (MRI)
- MRS. *See* Magnetic resonance spectroscopy (MRS)
- MTD. *See* Mean tumoral diameters (MTD)
- Multipotent adult stem cells (MASCs), 139, 154–156
- Multistage surgical approach
- diagnosis, 439
 - mechanisms, cerebral remapping, 440
 - postoperative functional neuroimaging, 349
 - “preventive” treatment, 440
- Multistage therapeutic approach, 438, 439

N

- Neural stem cells (NSCs), 77
- Neurofibromatosis type 1 (NF1), 487
- Neurosphere assay, 148–150
- NF1. *See* Neurofibromatosis type 1 (NF1)
- NSCs. *See* Neural stem cells (NSCs)

O

- Oligoastrocytomas (OAI), 107
- Oligodendrocyte precursor cells (OPCs)
 - chemotactic signals, 95
 - GBM, 95
 - migration, 94
 - tumorigenesis, 95
 - WAVE2, 94
- Oligodendrocyte progenitor cells (OPCs)
 - grade II gliomas, 84
 - Olig2+ marker, 84
 - p53/NF1 mutations, 83
- Oligodendroglioma tumors
 - chromosomal abnormalities, 102
 - chromosome, 101
 - clinical correlations, 106–107
 - EGFR* amplification, 105
 - G2Gs, 82
 - histologic variants, 101
 - isocitrate dehydrogenase, 105
 - loss of heterozygosity, 80–81
 - mitochondria, 80
 - neuronal markers, 81
 - Nogo-A, 80
 - 1p/19q candidate genes, 105
- OPCs. *See* Oligodendrocyte precursor cells (OPCs);
Oligodendrocyte progenitor cells (OPCs)
- OS. *See* Overall survival (OS)
- Overall survival (OS)
 - defined, 460, 461
 - vs.* deulking, 364
 - EOR, malignant transformation, 364
 - gross-total *vs.* subtotal resection, 364
 - IDLGG *vs.* DLGG, 481

P

- PCNSTs. *See* Primary central nervous system tumors (PCNSTs)
- PCV. *See* Procarbazine+cececu+vincristine (PCV)
- PDGF. *See* Platelet-derived growth factor (PDGF)
- PDGFR. *See* Platelet-derived growth factor receptor (PDGFR)
- Pediatric grade II infiltrative gliomas
 - adult, 108
 - genomic profiling studies, 108
 - WHO, 107
- Peritumoral cortex, 193–194
- Personalized medicine, 144, 156
- PET. *See* Positron emission tomography (PET)
- PFS. *See* Progression-free survival (PFS)

- PIHNA. *See* Proliferation-invasion-hypoxia-necrosis-angiogenesis (PIHNA)
- Planning target volumes (PTV), 428–429
- Platelet-derived growth factor (PDGF)
 - ALV, 170
 - GFAP, 170
 - human cell lines, 170
 - immature glial precursors, 166, 169
 - MAPK, 170
 - oligodendroglioma, 170
 - OPCs, 170
 - RCAS, 170
- Platelet-derived growth factor receptor (PDGFR), 104
- Positron emission tomography (PET)
 - cellular metabolism, 184
 - clinical applications, 236, 237
 - 3'-deoxy-3'-fluorothymidine (FLT), 185
 - description, 236
 - diagnostic assessment, recurrent tumors, 242
 - DLGGs (*see* Diffuse low-grade gliomas (DLGGs))
 - DTI, 244
 - DWI, 244
 - [¹⁸F]-fluoro-2-deoxy-D-glucose (FDG), 184, 185
 - glioma grading and prognosis, 241–242
 - hybrid PET-MRI systems, 244–245
 - low-grade gliomas, 184
 - MRI, 236
 - radio- and chemotherapy, 242–244
 - radiolabeled amino acids, 244
- Primary central nervous system tumors (PCNSTs)
 - coding systems, 11
 - generalities and definitions, 10
 - glioma morphology, 11
 - healthcare information systems, 21
 - methodology, 20
- Procarbazine+cececu+vincristine (PCV)
 - chemotherapy, 407
 - hematologic toxicity, 410
 - MTD, 418
 - quality of life (QOL), 410
- Prognostic scoring systems, 271
- Progression-free survival (PFS)
 - DLGG, 3
 - image-based, 460
 - overall survival, 2
 - TQL *vs.* malignant, 461, 462
- Proliferation-diffusion model
 - coefficient, 453
 - PIHNA, 455
 - tumoral cell density, 450
 - velocity of expansion, 452
- Proliferation-invasion-hypoxia-necrosis-angiogenesis (PIHNA), 455
- Prophylactic oncological neurosurgery. *See* Incidental diffuse low-grade gliomas (IDLGGs)
- Proteomic studies
 - advancing technologies, 118–119
 - LGGs (*see* Low-grade gliomas (LGGs))
- PTV. *See* Planning target volumes (PTV)

Q

QoL. *See* Quality of life (QoL)

Quality of life (QoL)

- control, seizures, 441
- functions and health-related, 379
- preservation, 438, 442
- resection and preservation, 382

R

Radiation therapy

- brainstem gliomas, 432
- and chemotherapy, 427–428
- conformal 3D-photon radiotherapy, 429
- dose, 427
- GBM, 425
- gliomatosis cerebri, 432–433
- particle, 430–431
- stereotactic, radiosurgery and IMRT, 429–430
- target volume definition, 428–429
- timing, 426–427
- treatment, recurrent tumors, 451

Radiolabeled amino acids, 236, 239, 240, 344

RBE. *See* Relative biological effectiveness (RBE)

RCAS. *See* Replication competent ALV splice (RCAS)

rCBVmax value

- Cho variation, 224
- LGGs, 224
- subgroups, 224

Relative biological effectiveness (RBE), 430

Replication competent ALV splice (RCAS), 170

S

Sainte Anne's Hospital classification

- components, 37
- endothelial hyperplasia, 38–39
- glioblastoma, 40
- grade II and III glioma, 41
- hemispheric tumors, 39
- microfoci, 42
- oligodendrocytes, 38
- oligodendrogliomas, 37–38
- WHO classification, 41
- WHO system, 39

Short-term cell lines, 145–146

“Site-specific” disorders, 293

SMA. *See* Supplementary motor area (SMA)

South Western Oncology Group (SWOG), 404

Speech-therapy, 282, 294

SRS. *See* Stereotactic radiosurgery (SRS)

Stereotactic radiosurgery (SRS), 429–430

Subventricular zone (SVZ)

- GBMs, 490
- gliomagenesis, OPC, 486
- OPC, 490
- tumors, 490

Supplementary motor area (SMA)

involvement, 484

planning, movements and language, 485

Supratotal resection

DLGG

- MR imaging signal abnormalities, 365–366
- objectives, 366
- value of reoperations, 367

IDLGG, left dominant hemisphere, 479, 480

Surgical resection, DLGG

cortico-subcortical mapping

- awake surgery, 369, 371
- brain glioma, 371
- preservation, subcortical connectivity, 370

EOR (*see* Extent of resection (EOR))

image-guided surgery, functional mapping-guides, 368–369

overall survival (OS), 364

postsurgical residual volume and EOR, 364, 365

subpial dissection and vasculature preservation, 371–373

supratotal resection, 365–366

SVZ. *See* Subventricular zone (SVZ)

SWOG. *See* South Western Oncology Group (SWOG)

T

TAF. *See* Tumor-associated fibroblasts (TAF)

Temozolomide (TMZ)

- CDT, 411
- chemotherapy, 404
- DLGG, 407
- drug assays, 145
- GSC, 154
- hepatitis, 412
- vs. radiotherapy, 415
- tolerance, 418
- volumic evolution, 417–418

Time with quality of life (TQL), 460–462

TMS. *See* Transcranial magnetic stimulation (TMS)

TMZ. *See* Temozolomide (TMZ)

TQL. *See* Time with quality of life (TQL)

Transcranial magnetic stimulation (TMS), 471

Tumor-associated fibroblasts (TAF), 139, 154

Tumor-associated parenchymal cell lines

- CAF, 154
- genetic fate-mapping, 154
- MASCs, 154, 155
- nonneoplastic stromal cells, 156
- stromal cells, 153
- TAF, 154
- TMZ, 154

Tumor-initiating cells, glioma-derived

- brain tumor cells, 146
- cell subpopulations, isolation, 147–148
- GSC, 146
- neurosphere assay, 148–150
- non-stem cell origin, 151–153
- stem cell lines, adherent culture, 150–151

U

Unilateral spatial neglect (USN), 290
USN. *See* Unilateral spatial neglect (USN)

V

VDE. *See* Velocity of diametric expansion (VDE)
Velocity of diametric expansion (VDE)
 defined, 452–453
 DLGG, 253–254
 kinetic classification, 456
 measurements, tumor, 455
 pretreatment, 256
 proliferation-diffusion model, 454

W

WHO II gliomas
 characteristics, 229
 low perfusion, 224
 “metabolic” subclasses, 229
 pathology, 225, 226

X

Xenograft models, low-grade gliomas
 IDH1-mutant anaplastic oligoastrocytoma, 173
 neurosphere-like cells, 172–173
 serial transplantations, 172